Sanggua tablets
Asset
TCM herbal formula that lowers blood glucose and improves lipid profiles
- Stage
- Phase 1
- Modality
- Supplement
- Target
- Insulin/IGF-1 signalling
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Impaired glucose tolerance
Phase 1, Recruiting, NCT06964620, clinicaltrials.gov, 7 Oct 2026
Type 2 diabetes
Phase 1, Recruiting, NCT06964620, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 1 source